[New antithrombotic drugs]

Ann Cardiol Angeiol (Paris). 2009 Dec:58 Suppl 1:S64-6. doi: 10.1016/S0003-3928(09)73405-5.
[Article in French]

Abstract

Many trials are ongoing in the field of thromboembolic event prevention in atrial fibrillation. These drugs are acting as antithrombin and antifactor Xa. The goal is to obtain drugs that could be as efficient as vitamine K antagonists but that could be more easily used, mainly by avoiding INR measurements.

Publication types

  • English Abstract

MeSH terms

  • Atrial Fibrillation / complications
  • Fibrinolytic Agents / therapeutic use*
  • Humans
  • Thrombosis / etiology
  • Thrombosis / prevention & control*

Substances

  • Fibrinolytic Agents